成熟商业化团队及分销网络构建，海外订单爆发式增长 精锋医疗于2017年5月在深圳创立，是中国自主研发手术机器人领域的深耕者，为中国首家、全球第二 家同时取得多孔腔镜手术机器人、单孔腔镜手术机器人及自然腔道手术机器人注册审批的公司，已构建 多孔+单孔+远程系统的"三合一"外科手术解决方案。公司全球首创的单多孔手术机器人超级系统 MSP2000已于2025年10月获得CE证，为全球手术机器人的技术演进与临床应用提供创新范本。 24年国内厂商销量第一，持续落地中国顶级医院圈层 自精锋多孔腔镜手术机器人于2022年12月商业化以来，于2024年在中国售出了20台精锋多孔腔镜手术机 器人，在国内手术机器人制造商中排名第一，临床应用范围已覆盖全国30个省份，超过220家医院，包 括国内顶尖三甲医院乃至多个省份的县域基层医院，实现了"省-市-县"三级医院网络的全覆盖。伴随国 内销量大幅增长以及海外的商业化，公司总收入由2023年的0.48亿元增加至2024年的1.6亿元，并由 2024H1的0.30亿元增加至2025H1的1.49亿元。 国泰海通证券发布研报称，首次覆盖精锋医疗-B(02675)给予评级为"增持"。预测公司 ...

自精锋多孔腔镜手术机器人于2022年12月商业化以来，于2024年在中国售出了20台精锋多孔腔镜手术机 器人，在国内手术机器人制造商中排名第一，临床应用范围已覆盖全国30个省份，超过220家医院，包 括国内顶尖三甲医院乃至多个省份的县域基层医院，实现了"省-市-县"三级医院网络的全覆盖。伴随国 内销量大幅增长以及海外的商业化，公司总收入由2023年的0.48亿元增加至2024年的1.6亿元，并由 2024H1的0.30亿元增加至2025H1的1.49亿元。 智通财经APP获悉，国泰海通证券发布研报称，首次覆盖精锋医疗-B(02675)给予评级为"增持"。预测公 司2025-2027年的收入分别为4.32、8.11、12.36亿元，参考可比公司，考虑公司产品布局领先，海外进 展迅速，给予公司2026年35XPS，对应目标价73.20元/79.57港元（汇率为1港元=0.92人民币）。 国泰海通证券主要观点如下： 国产手术机器人引领者，持续革新推动技术进步 精锋医疗于2017年5月在深圳创立，是中国自主研发手术机器人领域的深耕者，为中国首家、全球第二 家同时取得多孔腔镜手术机器人、单孔腔镜手术机器人及自然腔道手术 ...

Investment Rating - The report assigns an "Accumulate" rating to the company [1][11][6]. Core Insights - The company is a leader in domestic surgical robotics, driving advancements in surgical procedures through continuous technological innovation. With rapid growth in global clinical surgical volumes, the company is experiencing significant revenue growth alongside increasing domestic sales and commercialization in overseas markets [2][11]. Summary by Sections 1. Domestic Surgical Robotics Leader - The company was founded in May 2017 in Shenzhen and is the first in China and the second globally to obtain regulatory approval for multi-port, single-port, and natural orifice surgical robots. It has developed a "three-in-one" surgical solution combining multi-port, single-port, and remote systems [15][11]. - The company has achieved the highest sales volume among domestic manufacturers in 2024, with 20 units of its multi-port surgical robot sold in China, covering over 220 hospitals across 30 provinces [11][29]. - Revenue is projected to grow from RMB 0.48 billion in 2023 to RMB 1.6 billion in 2024, driven by increased sales and market acceptance of its products [29][30]. 2. Clinical Advantages of Surgical Robots - Surgical robots provide significant clinical benefits, including high precision, stability, and repeatability, which traditional laparoscopic surgeries struggle to achieve. This technology is transforming the landscape of minimally invasive surgeries [38][39]. 3. International Expansion and Sales Growth - The company has successfully entered overseas markets, securing five orders in 2024 and establishing a distribution network across five continents. By the end of 2025, it had signed global sales agreements for 118 units, with 72 units designated for international markets [11][29]. - The company’s internationalization efforts have marked a transition from initial market testing to large-scale expansion [11][29]. 4. Financial Projections - Revenue forecasts for 2025, 2026, and 2027 are RMB 4.32 billion, RMB 8.11 billion, and RMB 12.36 billion, respectively, reflecting substantial growth rates of 170% and 88% in the following years [4][11]. - The company is expected to turn profitable by 2026, with net profit projected to reach RMB 167 million by 2027, following a loss of RMB 219 million in 2024 [4][11]. 5. Management Team and R&D Strength - The management team, led by experienced founders, has built a proprietary technology platform supported by a multidisciplinary R&D team of 265 members. The company holds the highest number of patents in the Chinese surgical robotics sector [20][25]. - The company has established a comprehensive technology platform based on seven proprietary core technology modules, enhancing its competitive edge in the market [26][27].

本周医药板块表现弱于整体市场，医药商业降幅居前。本周全部 A 股下 跌 0.98%（总市值加权平均），沪深 300 上涨 0.08%，中小板指下跌 3.78%，创业板指下跌 0.09%，生物医药板块整体下跌 3.31%，生物医 药板块表现弱于整体市场。分子板块来看，化学制药下跌 3.20%，生物 制品下跌 2.50%，医疗服务下跌 4.15%，医疗器械下跌 3.86%，医药商 业下跌 4.49%，中药下跌 1.94%。医药生物市盈率（TTM）37.27x，处 于近 5 年历史估值的 80.47%分位数。 精锋医疗为领先的手术机器人公司。精锋医疗成立于 2017 年，是中国 首家、全球第二家同时取得多孔腔镜、单孔腔镜及自然腔道三类手术机 器人注册审批的领先企业，2024 年斩获国内手术机器人制造商销量第 一，2026 年 1 月于香港联交所挂牌上市。公司核心管理层具备深厚的 行业经验与国际背景，全球专利布局超 734 项，技术实力雄厚。 精锋医疗构建了覆盖多科室的丰富管线。多孔系列 MP1000 及升级款 已获批多专科应用并实现商业化放量，单孔系列 SP1000 为国内首个 覆盖三大外科的国产单孔机器人，支气管 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [4] Core Insights - The surgical robot market is expected to grow significantly, driven by technological innovation, clinical demand, and policy benefits, particularly in China where the penetration rate is projected to increase from 0.7% in 2024 to 3.0% by 2033 [20][29] - Jingfeng Medical is a leading surgical robot company in China, having achieved significant milestones including the first domestic sales ranking in 2024 and a successful listing on the Hong Kong Stock Exchange in January 2026 [1][10] - The company has a robust pipeline of products across multiple specialties, with its multi-port and single-port surgical robots already commercialized and showing strong sales growth [2][34] Summary by Sections Market Performance - The overall pharmaceutical sector underperformed the market, with a decline of 3.31% in the biopharmaceutical sector, while the A-share market saw an average decline of 0.98% [1] - The TTM price-to-earnings ratio for the biopharmaceutical sector stands at 37.27x, which is at the 80.47th percentile of the past five years [1] Company Overview - Jingfeng Medical was established in 2017 and is the first in China and the second globally to obtain regulatory approval for multi-port, single-port, and natural orifice surgical robots [10] - The company has over 734 global patents, showcasing its strong technological capabilities and commitment to innovation [35] Product Pipeline - The company has developed a diverse product line, including the MP1000 multi-port robot and the SP1000 single-port robot, which are approved for various surgical applications [2][10] - The CP1000 bronchoscopic robot is an innovative product aimed at non-invasive diagnosis and treatment of lung diseases, with significant clinical advantages [31][34] Financial Projections - Jingfeng Medical's revenue for the first half of 2025 reached 149 million RMB, a year-on-year increase of 394%, with surgical robot sales accounting for 92.9% of total revenue [34] - The company is expected to continue its growth trajectory with increasing overseas orders and expanding market presence [35] Competitive Landscape - The multi-port surgical robot market is currently dominated by Intuitive Surgical, which holds an 83% market share, while domestic competitors are rapidly emerging [26] - The single-port robot market is still in its early stages, with Jingfeng Medical holding a first-mover advantage in China [28]

Investment Rating - The report does not explicitly state an investment rating for the surgical robot industry, but it highlights a positive outlook for growth and innovation in the sector. Core Insights - The surgical robot industry in China is entering a rapid development phase, supported by national policies and capital investment, with significant advancements in technology and market demand [13]. - The report emphasizes the transition from a capital-driven to a value-driven model in the surgical robot sector, indicating a shift towards more sustainable growth and clinical applications [13]. - The approval process for surgical robots by the NMPA has accelerated, particularly for domestic products, with orthopedic surgical robots leading in the number of approvals [30]. Summary by Sections Market Overview - The surgical robot market in China is characterized by a growth in sales volume, with a total of 332 units sold in the first 11 months of 2025, reflecting a year-on-year increase of 3.75% [34]. - The sales revenue for surgical robots reached 2.973 billion yuan, showing a slight decline of 0.87% year-on-year, indicating a structural transition rather than a market downturn [34]. Technological Advancements - Innovations in remote operation, miniaturization, and AI assistance are driving the development of surgical robots, with notable products like the first remote surgical robot approved in China [16][19]. - The report highlights the introduction of AI-assisted surgical robots that enhance precision and efficiency in surgeries, marking a significant technological leap in the industry [16]. Regulatory Developments - The National Healthcare Security Administration has established a pricing framework for surgical robots, which is expected to facilitate market growth by clarifying reimbursement policies and pricing structures [27][26]. - The report notes that the establishment of a clear payment system is crucial for the adoption of surgical robots in hospitals, as high costs and long return periods can deter procurement [27]. Market Segmentation - The orthopedic surgical robot segment dominates the market, accounting for 50% of the NMPA approvals from 2014 to 2024, with a strong growth trajectory expected in this area [30]. - The report identifies the laparoscopic surgical robot and orthopedic surgical robot as the two largest segments in the market, with significant potential for expansion in emerging fields [41]. Future Outlook - The report projects substantial growth in the surgical robot market, with expectations for increased penetration rates and market size driven by technological advancements and policy support [44]. - The anticipated CAGR for the laparoscopic surgical robot market from 2024 to 2033 is estimated at 30.4%, indicating robust future demand [44].

Core Viewpoint - The Chinese surgical robot industry is entering a rapid development phase, driven by policy support, capital investment, and technological advancements, with significant progress in various fields such as orthopedics and neurosurgery [13][21]. Market Overview - The CITIC Medical Index fell by 3.33% this week, underperforming the CSI 300 Index by 3.41 percentage points, ranking 22nd among 30 primary industries [8]. - The top ten stocks by growth this week included Cap Bio, Hualan Biological, and Dezheng Health, while the biggest losers were *ST Sailong and Vcare Pharmaceuticals [8]. Industry and Company Events - The surgical robot market is characterized by a shift from capital-driven to value-driven development, with increasing applications in remote surgery and AI-assisted decision-making [13][21]. - The NMPA has accelerated the approval of surgical robots, with orthopedic surgical robots accounting for 50% of the approved products from 2014 to 2024, maintaining the highest share [22]. Investment Themes - The innovative drug sector is transitioning from quantity to quality, emphasizing differentiated products and internationalization by 2025 [11]. - The medical device sector is witnessing a recovery in bidding volumes for imaging equipment, with ongoing updates in home medical devices supported by subsidies [11]. - The CXO and life sciences services are expected to see a rebound in investment, with a focus on high-profit elasticity companies as the industry matures [11]. Technological Progress - Remote operation, miniaturization, and AI assistance are key trends in the surgical robot sector, with products like the TUMAI® remote surgical robot achieving significant milestones in cross-border surgeries [17][19]. - The first AI-assisted orthopedic surgical robot, ROPA HIP, has been approved, showcasing advancements in surgical simulation technology [17]. Regulatory Developments - The National Medical Insurance Administration (NMPA) has established a pricing system for surgical robots, which is expected to enhance the industry's growth by clarifying reimbursement standards [21]. - The introduction of a legal and clear pricing project for surgical robots is anticipated to provide institutional support for innovation and development in the industry [21]. Sales and Market Dynamics - The sales volume of surgical robots in China reached 332 units in the first 11 months of 2025, reflecting a 3.75% year-on-year increase, while sales revenue decreased by 0.87% [27]. - The orthopedic surgical robot segment showed a significant growth of 17.81% in volume and 21.62% in revenue, indicating a robust demand in specialized fields [27]. Market Segmentation - The market for surgical robots is dominated by laparoscopic and orthopedic surgical robots, which accounted for 42% and 32% of the market share, respectively, in 2024 [25]. - Emerging fields such as vascular surgery robots are expected to present substantial market potential as the industry evolves [27].

Core Viewpoint - The medical sector is showing signs of recovery in 2026, driven by policy clarity and the realization of innovative outcomes, leading to increased investment interest in medical ETFs [1][19]. Group 1: Current Core Logic and Positive Factors in the Medical Sector - The transition from "selling expectations" to "performance realization" is evident, with domestic medical device innovations gaining global recognition, thus becoming a new growth engine for the industry [3][21]. - The medical sector is experiencing a high proportion of companies meeting or exceeding their 2025 performance forecasts, indicating a favorable industry outlook [3][21]. - The recent surge in AI medical technologies is not just speculative but demonstrates clear cost-reduction and efficiency-enhancing capabilities in hospital operations and drug development [4][23]. Group 2: Policy Environment Changes - The policy environment has shifted from a "speed over quality" approach to one of "value co-creation," with recent signals indicating a more favorable stance on centralized procurement and medical insurance negotiations [6][24]. - Optimizations in the approval process for innovative medical devices and continuous improvements in procurement rules are expected to enhance the competitive landscape and restore profitability for companies [8][26]. - The introduction of a market exclusivity period in the revised Drug Administration Law is expected to boost long-term investment confidence in pharmaceutical R&D [9][27]. Group 3: Financial Support for Medical Equipment Updates - The national "two new" policy, focusing on large-scale equipment updates and consumer goods replacement, has allocated 62.5 billion yuan in special bonds to support medical equipment upgrades, benefiting listed companies in the medical device sector [10][28]. - There is a significant demand for replacing outdated medical equipment in domestic healthcare institutions, coupled with policies favoring domestic alternatives, leading to increased orders and market share for leading companies in imaging, surgical robots, and in-vitro diagnostics [10][28]. Group 4: Reasons for Recent Fund Inflows into Medical ETF (512170) - The medical ETF (512170) has seen substantial inflows, with a single-day capital increase of 499 million yuan on January 28, 2026, and a total of 1.8 billion yuan over nine consecutive trading days, reflecting a shift in market sentiment towards value recovery [1][19][14]. - The medical ETF is currently one of the largest medical-themed ETFs in A-shares, with a market size exceeding 26 billion yuan, driven by high cost-effectiveness and a consensus on bottom valuations [14][32]. - The ETF closely tracks the CSI Medical Index, with significant allocations in medical devices (53.17%) and medical services, making it an attractive option for both institutional and retail investors [14][32][34].

Group 1 - The core viewpoint of the news is that Tianzhihang, known as the "first stock of surgical robots," anticipates significant revenue growth in 2025, despite expected net losses [1] - Tianzhihang projects a revenue of 270 million to 300 million yuan for 2025, representing a year-on-year increase of 50.97% to 67.75% [1] - The expected increase in revenue is attributed to a recovering market environment and substantial growth in product sales and technical service income [1] Group 2 - The company expects a net loss of 165 million to 198 million yuan for 2025, with the loss widening due to reduced investment income, increased share-based payment expenses, and higher income tax expenses [1] - The Tianji orthopedic surgical robot is projected to perform over 49,000 surgeries in 2025, building on the 39,000 surgeries conducted in 2024, with a cumulative total exceeding 150,000 surgeries [1] - The orthopedic surgical robot market in China is expected to see over 100 units awarded in procurement by 2025, with a market growth rate of approximately 35% year-on-year [2] Group 3 - Tianzhihang maintains a leading position in the domestic orthopedic surgical robot market, with a market share exceeding 40% [2] - The successful completion of China's first "spatial computing + orthopedic surgical robot" surgery marks a significant advancement in intelligent orthopedic diagnosis and treatment technology [2] - Recent policy changes, including a unified pricing framework for robotic surgeries, are expected to empower the entire surgical robot industry, with orthopedic surgical robots likely to be the primary beneficiaries due to strong clinical demand and a large patient base [2]

Core Viewpoint - The surgical robot industry is experiencing accelerated commercialization driven by both policy support and increasing demand [1][2] Group 1: Company Performance - Tianzhihang, known as the "first stock of surgical robots," forecasts a revenue of 270 million to 300 million yuan for 2025, representing a growth of 50.97% to 67.75% compared to the previous year [1] - The company expects a net loss attributable to shareholders of 165 million to 198 million yuan, which is an increase in losses compared to the previous year [1] - The significant revenue growth is attributed to a recovering market environment and increased sales and technical service income [1] Group 2: Market Dynamics - The Tianji orthopedic surgical robot is projected to perform over 49,000 surgeries in 2025, continuing growth from 39,000 surgeries in 2024, with a cumulative total exceeding 150,000 surgeries [1] - The acceptance of surgical robots in the industry is increasing due to advancements by leading manufacturers in technology, service, product maturity, and business models [2] - The orthopedic surgical robot segment is recognized as one of the more mature areas within the surgical robot market, maintaining a leading position in commercialization [2] Group 3: Industry Trends - The domestic market for orthopedic surgical robots is expected to see over 100 units awarded in procurement by 2025, with a market growth rate of approximately 35% year-on-year [2] - Tianzhihang holds a leading market share of over 40% in the domestic orthopedic surgical robot market [2] - Recent policy changes, including a unified pricing framework for robotic surgeries, are anticipated to provide systemic support for the entire surgical robot industry, with orthopedic surgical robots likely to be the primary beneficiaries due to strong clinical demand and a large patient base [2]